Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free

Glaukos

NYSE GKOS
$109.27 -0.52 -0.48%
Today share price
USA
Sector: Healthcare Industry: Health Care Equipment & Supplies
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 23 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

5.42B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
5.61B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.76
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
49.58M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
37.46 %

Upcoming events Glaukos

All events
No upcoming events scheduled

Overview

Financials

Key Metrics

Dividends

Industry overview

Events

Stock chart Glaukos

Stock analysis Glaukos

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-38.46 38.22
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.
11.73 3.15
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-70.02 18.93
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
-2.38 2.02
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-31.25 8.18

Price change Glaukos per year

45.11$ 99.00$
Min Max

Summary analysis Glaukos

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Glaukos

Revenue and net income Glaukos

All parameters

Stock news Glaukos

All news
14 December 2023 в 15:40

FDA Approves Glaukos' New Drug Application for iDose TR

14 December 2023 в 15:40

FDA Approves Glaukos' New Drug Application for iDose TR

27 February 2023 в 15:30

Glaukos Submits FDA New Drug Application for IDose TR

27 February 2023 в 15:30

Glaukos Submits FDA New Drug Application for IDose TR

7 September 2022 в 16:23

Glaukos Sees Positive Data From Phase 3 Trials for iDose TR

7 September 2022 в 16:22

Glaukos Sees Positive Data From Phase 3 Trials for iDose TR

12 July 2022 в 14:30

Glaukos stock price target raised to $60 from $40 at Stifel Nicolaus

20 September 2021 в 15:40

Glaukos in Licensing Agreement With Attillaps Holdings

20 September 2021 в 15:35

Glaukos in Licensing Agreement With Attillaps Holdings

15 September 2021 в 15:10

Glaukos Settles Patent Infringement Lawsuit Against Ivantis

15 September 2021 в 15:10

Glaukos Settles Patent Infringement Lawsuit Against Ivantis

22 July 2021 в 18:09

What’s Next For Glaukos After A Large 35% Drop In A Week?

About company Glaukos

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.
Address:
229 Avenida Fabricante, San Clemente, CA, United States, 92672
Company name: Glaukos
Issuer ticker: GKOS
ISIN: US3773221029
Country: USA
Exchange: NYSE
Currency: $
IPO date: 2015-06-25
Sector: Healthcare
Industry: Health Care Equipment & Supplies
Site: https://www.glaukos.com

On which stock exchange are Glaukos (GKOS) stocks traded?

Glaukos (GKOS) stocks are traded on NYSE.

What is the ticker of Glaukos stocks (GKOS)?

The stock ticker of Glaukos’s stocks or in other words, the code is GKOS. The stocks are currently listed on the NYSE exchange.

In which sector and industry does Glaukos (GKOS) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Glaukos (GKOS) belongs to the «Healthcare» sector and the «Health Care Equipment & Supplies» industry.

In what currency are Glaukos (GKOS) stocks traded?

Glaukos (GKOS) stocks are traded on the NYSE exchange in dollars.

What is the price of Glaukos (GKOS) stocks today?

The current price of Glaukos stocks on 21.05.2024 is 109.27 dollars. per share.

What is the dynamics of Glaukos (GKOS) stocks from the beginning of the year?

Glaukos (GKOS) quotes have increased by 41.76% from the beginning of the year up to 109.27 dollars. per 1 stocks.

How much did Glaukos (GKOS) stocks increase in мае 2024?

This month Glaukos (GKOS) quotes have increased by 10.47% to 109.27 dollars. per share.

How much are Glaukos (GKOS) stocks worth?

Today, on October, 21.05.2024 Glaukos’s (GKOS) stocks cost 109.27 dollars..

What is the market capitalization of Glaukos (GKOS)?

Capitalization is the market value of Glaukos (GKOS) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 21.05.2024, the market capitalization of Glaukos (GKOS) is estimated at about 5417606600 dollars.